Shuttle Pharmaceuticals is expected to report zero revenue and a consensus EPS loss of $4.30 for Q2 2026, with the stock trading at $4.36 relative to a depressed analyst price target of $0.49.
The primary focus for investors is the company’s recent and controversial strategic pivot from oncology drug development to Dogecoin mining following its acquisition of United Dogecoin Inc.
This shift effectively terminated the company's Phase 2 glioblastoma clinical trials in late 2025, a move that has alienated traditional biotech investors and triggered extreme volatility in the low-float stock.
With a reported working capital deficit of $5.8 million and only $1.09 million in cash remaining, the upcoming report will be scrutinized for the financial impact of its crypto-mining operations and its overall viability as a going concern.